Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced it will host a virtual key opinion leader (KOL)
event focused on its Enzyme-Catalyzed Oligonucleotide (ECO)
Synthesis™ platform and the broader RNA interference (RNAi)
therapeutics manufacturing landscape on Friday, December 8, 2023,
at 10:00 am ET.
The event will feature John Maraganore, PhD,
Founder and Former Chief Executive Officer of Alnylam
Pharmaceuticals, and David Butler, PhD, Chief Technology Officer at
Hongene Biotech Corporation. These distinguished experts will
discuss the RNAi therapeutics manufacturing landscape and share
their perspectives on the potential role of an enzymatic route of
synthesis in commercial-scale production. During the event, Codexis
management will also provide an overview of the ECO Synthesis™
platform and the associated commercial opportunity. A live Q&A
session with all presenters will follow the formal
presentations.
To register for the event, please click here. A
replay of the presentation will be archived in the Investor
Relations section of the Company’s
website, https://ir.codexis.com, following the event.
About John Maraganore, PhD
John Maraganore, PhD, served as the founding CEO
and a Director of Alnylam from 2002 to 2021, where he built and led
the company from early platform research on RNA interference
through global approval and commercialization of the first five
RNAi therapeutics, creating a whole new class of medicines. At
Alnylam, Dr. Maraganore built a leading, global biopharmaceutical
company with over 1500 employees in over 20 countries around the
world. He led the company’s value creation strategy, building over
$25B in market capitalization. Prior to Alnylam, he held scientific
and business leadership roles at Millennium Pharmaceuticals, Inc.;
at Biogen, Inc. where he invented and led the discovery and
development of ANGIOMAX® (bivalirudin); at ZymoGenetics, Inc.; and
at the Upjohn Company. Dr. Maraganore is currently the principal
and owner of JMM Innovations, LLC. He serves as an advisor to a
number of venture and public company investment firms, and as a
member of the Board of Directors of multiple publicly traded
companies, including Beam Therapeutics, Kymera Therapeutics,
ProKidney Corp., and Takeda Pharmaceuticals. He is on the Board of
a number of private companies and non-profit organizations, and
also serves as a strategic advisor to other public and private
biotechnology companies. Finally, Dr. Maraganore is on the Board of
the Biotechnology Innovation Organization, or “BIO,” where he was
Chair from 2017-2019 and is Chair Emeritus. Dr. Maraganore received
his BA, MS, and PhD in biochemistry and molecular biology at the
University of Chicago.
About David Butler, PhD
David Butler, PhD, is the Chief Technology
Officer at Hongene Biotech Corporation, a fully integrated supplier
of raw materials and contract development and manufacturing
organization (CDMO) services to customers in the RNA therapeutics
space, the scope of which includes mRNA, vaccines,
oligonucleotides, gene editing, gene therapy and diagnostics. Prior
to Hongene, Dr. Butler led organizations driving platform discovery
and development of oligonucleotide therapeutics as Vice President
(VP) and Head of Medicinal Chemistry at Wave Life Sciences, VP and
Head of Therapeutics Development at Alltrna, and VP and Head of
Chemistry at Korro Bio. He also spent time as a Principal Scientist
at Alnylam Pharmaceuticals developing early lipid nanoparticle
technologies for small interfering RNA delivery that were the
progenitors of those used for messenger RNA related products
today.
About the ECO Synthesis™
Platform
Ribonucleic acid (RNA) as a therapeutic modality
has gained tremendous traction in recent years with the growing
number of messenger RNA (mRNA) vaccines and small interfering RNA
(siRNA) candidates advancing in clinical studies. However,
large-scale production of RNA interference (RNAi) therapeutics
using traditional chemical synthesis faces complex challenges in
nucleic acids quality and quantity, as well as overall economics.
With over 450 RNAi therapies currently in clinical development,
including more than 40 assets in Phase 2 and Phase 3 clinical
trials targeting disease indications impacting millions of
patients, RNAi therapeutic demand is projected to outpace current
production capabilities by the end of the decade. Codexis’
proprietary ECO Synthesis™ technology platform is being designed to
address these scalability and cost limitations by potentially
enabling the commercial-scale manufacture of RNAi therapeutics
through an enzymatic route. The Company is on track to demonstrate
gram-scale synthesis by the end of 2023, where it will demonstrate
the preparative-scale manufacture of an oligonucleotide, composed
of the modified nucleotide building blocks typically used in RNAi
therapeutics, under process-like conditions.
About Codexis
Codexis is a leading enzyme engineering company
leveraging its proprietary CodeEvolver® technology platform to
discover, develop and enhance novel, high-performance enzymes and
other classes of proteins. Codexis enzymes solve for real-world
challenges associated with small molecule pharmaceuticals
manufacturing and nucleic acid synthesis. The Company is currently
developing its proprietary ECO Synthesis™ platform to enable the
scaled manufacture of RNAi therapeutics through an enzymatic route.
Codexis’ unique enzymes can drive improvements such as higher
yields, reduced energy usage and waste generation, improved
efficiency in manufacturing and greater sensitivity in genomic and
diagnostic applications. For more information, visit
https://www.codexis.com.
Forward-Looking Statements
This press release may contain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. In some cases, you can identify
forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “suggest,” “target,” “on track,” “will,” “would”
and other similar expressions that are predictions of or indicate
future events and future trends, or the negative of these terms or
other comparable terminology. To the extent that statements
contained in this press release are not descriptions of historical
facts, they are forward-looking statements reflecting the current
beliefs and expectations of management, including but not limited
to statements regarding whether Codexis will be able to, and the
timing of it demonstrating gram-scale synthesis with its ECO
Synthesis™ technology by the end of 2023; the potential of the ECO
Synthesis™ platform, including its ability to be broadly utilized,
and it providing an opportunity for Codexis to efficiently capture
meaningful market share; and expectations regarding future demand
for RNAi technologies. You should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties and other factors that are, in some cases,
beyond Codexis’ control and that could materially affect actual
results. Factors that could materially affect actual results
include, among others: Codexis’ dependence on its licensees and
collaborators; if any of its collaborators terminate their
development programs under their respective license agreements with
Codexis; Codexis may need additional capital in the future in order
to expand its business; if Codexis is unable to successfully
develop new technology such as its ECO Synthesis™ platform;
Codexis' dependence on a limited number of products and customers,
and potential adverse effects to Codexis’ business if its
customers’ products are not received well in the markets; if
Codexis is unable to develop and commercialize new products for its
target markets; if competitors and potential competitors who have
greater resources and experience than Codexis develop products and
technologies that make Codexis’ products and technologies obsolete;
if Codexis is unable to accurately forecast financial and
operational performance; and market and economic conditions may
negatively impact Codexis' business, financial condition and share
price. Additional information about factors that could materially
affect actual results can be found in Codexis’ Annual Report on
Form 10-K filed with the Securities and Exchange Commission (“SEC”)
on February 27, 2023 and in Codexis’ Quarterly Report on Form 10-Q
filed with the SEC on November 3, 2023, including under the caption
“Risk Factors,” and in Codexis’ other periodic reports filed with
the SEC. Codexis expressly disclaims any intent or obligation to
update these forward-looking statements, except as required by
law.
For More Information
Investor ContactCarrie McKim(336)
608-9706ir@codexis.com
Media ContactLauren Musto(781)
572-1147media@codexis.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024